Analyze Etiology, Comorbidities, Clinical Characteristics
Conditions
Brief summary
The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.
Detailed description
Inclusion criteria: 1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance; 2. Signs of fluid retention (pulmonary congestion and peripheral edema); 3. Echocardiography shows abnormalities in cardiac structure and/or function; 4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L. 5. HF hospitalization recorded within the previous 12 months Exclusion criteria: 1. Concomitant severe liver function, renal failure, or other severe system dysfunction 2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Interventions
OTHERNo Intervention
no intervention
Sponsors
Xiang Xie
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance; 2. Signs of fluid retention (pulmonary congestion and peripheral edema); 3. Echocardiography shows abnormalities in cardiac structure and/or function; 4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
Exclusion criteria
1. Concomitant severe liver function, renal failure, or other severe system dysfunction 2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| echocardiogram | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | ejection fraction,Consider heart failure when the ejection fraction is less than 50% |
| cardiac marker | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | CK，CK-MB，cTnT，cTnI，Mb |
| serum biochemical indicators | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | HDL-cholesterol, mg/dL，LDL-cholesterol, mg/dL，Total cholesterol, mg/dL，Triglycerides, mg/dL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thyroid Function | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | thyroid hormone,Thyroid hormone blood testing: This is the most commonly used method to measure thyroid hormone levels in the blood. Common thyroid hormone indicators include thyroxine, free thyroxine, triiodothyronine, and free triiodothyronine. |
| Coagulation function indicators | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | D-Dimer |
| Blood routine | Follow up will be conducted at baseline, 6 months, 12 months, and 36 months | RBC |
Outcome results
None listed